文献速递肝病

比较20%白蛋白与勃脉力在肝硬化合并脓毒症诱导低血压患者中的随机对照试验(ALPS试验)

A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial].
PubMed 文献 · J Hepatol · 2022-04-20

在肝硬化合并脓毒症诱导低血压的危重患者中,20%白蛋白组3小时平均动脉压达标率62%优于勃脉力组22%(p<0.001),动脉乳酸下降更快,但28天死亡率无差异(58% vs 62%,p=0.57),且白蛋白组11例(22%)因不良反应停药并更多见肺部并发症。

要点

  • 20%白蛋白3小时平均动脉压达标率62%,优于勃脉力22%(p<0.001)。
  • 白蛋白组动脉乳酸下降更快(p=0.03),但28天死亡率无差异(58% vs 62%,p=0.57)。
  • 白蛋白组11例(22%)因不良反应停药,勃脉力组无停药,白蛋白更常伴肺部并发症。

核心结论

  • 在肝硬化合并脓毒症诱导低血压患者中,20%白蛋白较勃脉力更快改善血流动力学和乳酸清除,但28天生存率相似。
  • 使用20%白蛋白的患者需要密切监测,因其更常与肺部并发症相关。

研究设计与样本

  • 开放标签随机对照试验,纳入危重肝硬化合并脓毒症诱导低血压患者,20%白蛋白组n=50,勃脉力组n=50。
  • 20%白蛋白剂量为0.5-1.0 g/kg,3小时内输注;勃脉力为30 ml/kg,3小时内输注。
  • 主要终点为3小时时平均动脉压(MAP)高于65 mmHg的达标情况。
  • 临床试验注册号NCT02721238。

主要发现

  • 基线特征两组可比:动脉乳酸6.16±3.18 mmol/L vs 6.38±4.77 mmol/L(p=0.78),MAP 51.4±6.52 mmHg vs 49.9±4.45 mmHg(p=0.17),SOFA评分10.8±2.96 vs 11.1±4.2(p=0.68)。
  • 多数患者为酒精性(39%)和肺炎(40%)。
  • 意向性治疗分析中,白蛋白组主要终点达标率62%优于勃脉力组22%(p<0.001)。
  • 白蛋白组动脉乳酸下降更快(p=0.03),透析需求48% vs 62%(p=0.16),开始透析时间(小时)68.13±47.79 vs 99.7±63.4(p=0.06)。
  • 28天死亡率无差异(58% vs 62%,p=0.57);白蛋白组11例(22%)因不良反应停药,勃脉力组无停药。

关键数值与推荐

  • 20%白蛋白给药方案:0.5-1.0 g/kg,3小时内输注。
  • 勃脉力给药方案:30 ml/kg,3小时内输注。
  • 主要终点:3小时时MAP高于65 mmHg。
  • 白蛋白组主要终点达标率62% vs 勃脉力组22%(p<0.001)。
  • 28天死亡率58% vs 62%(p=0.57)。

临床怎么用

  • 作者在总结中指出,勃脉力更安全且耐受性良好,可考虑用于肝硬化合并脓毒症诱导低血压患者的容量复苏。
  • 作者在结论中建议,使用20%白蛋白的患者需要密切监测,因其更常与肺部并发症相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The choice of resuscitation fluid in patients with cirrhosis and sepsis-induced hypotension is unclear. 5% albumin was superior to normal saline in the FRISC study. We compared the efficacy and safety of 20% albumin, which has greater oncotic properties, to plasmalyte in reversing sepsis-induced hypotension. METHODS: Critically ill patients with cirrhosis underwent open-label randomization to receive either 20% albumin (0.5-1.0 g/kg over 3 hours; n = 50) or plasmalyte (30 ml/kg over 3 hours, n = 50). The primary endpoint of the study was the attainment of mean arterial pressure (MAP) above 65 mmHg at 3 hours. RESULTS: Baseline characteristics were comparable in albumin and plasmalyte groups; arterial lactate (6.16±3.18 mmol/L vs. 6.38±4.77 mmol/L; p = 0.78), MAP (51.4±6.52 mmHg vs. 49.9±4.45 mmHg; p = 0.17) and SOFA score (10.8±2.96 vs. 11.1±4.2; p = 0.68), respectively. Most patients were alcoholics (39%) and had pneumonia (40%). In the intention-to-treat analysis, albumin was superior to plasmalyte in achieving the primary endpoint (62% vs. 22%; p <0.001). A faster decline in arterial lactate (p = 0.03), a reduced need for dialysis (48% vs. 62%; p = 0.16), and a longer time to initiation of dialysis (in hours) (68.13±47.79 vs. 99.7± 63.4; p = 0.06) were seen with albumin. However, the 28-day mortality rate was not different (58% vs. 62%, p = 0.57) and treatment had to be discontinued in 11 (22%) patients in the albumin group due to adverse effects compared to no discontinuations in the plasmalyte group. CONCLUSION: In patients with cirrhosis and sepsis-induced hypotension, 20% albumin leads to a faster improvement in hemodynamics and lactate clearance than plasmalyte, while 28-day survival was similar. However, patients on 20% albumin need to be closely monitored as it was more often associated with pulmonary complications. CLINICAL TRIAL REGISTRATION: NCT02721238. LAY SUMMARY: The current randomized-controlled trial performed in critically ill patients with cirrhosis and sepsis-induced hypotension highlights that 20% albumin restores arterial pressure more quickly but causes more pulmonary complications than plasmalyte. The impact on renal functions was also modest. These effects did not result in improvement in survival at 28 days. Plasmalyte is safer and well-tolerated and can be considered for volume resuscitation in patients with cirrhosis and sepsis-induced hypotension.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Maiwall R, Kumar A, Pasupuleti SSR, et al. A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension [ALPS trial]. J Hepatol. 2022. PMID: 35460725. doi:10.1016/j.jhep.2022.03.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。